323 related articles for article (PubMed ID: 18020620)
1. Progress and challenges towards the development of malaria vaccines.
Tetteh KK; Polley SD
BioDrugs; 2007; 21(6):357-73. PubMed ID: 18020620
[TBL] [Abstract][Full Text] [Related]
2. The case for a subunit vaccine against malaria.
Anders RF
Trends Parasitol; 2011 Aug; 27(8):330-4. PubMed ID: 21592861
[TBL] [Abstract][Full Text] [Related]
3. The Plasmodium sporozoite survives RTS,S vaccination.
Snounou G; Grüner AC; Müller-Graf CD; Mazier D; Rénia L
Trends Parasitol; 2005 Oct; 21(10):456-61. PubMed ID: 16109504
[TBL] [Abstract][Full Text] [Related]
4. Vaccination With Sporozoites: Models and Correlates of Protection.
Goh YS; McGuire D; Rénia L
Front Immunol; 2019; 10():1227. PubMed ID: 31231377
[TBL] [Abstract][Full Text] [Related]
5. Development of whole sporozoite malaria vaccines.
Hollingdale MR; Sedegah M
Expert Rev Vaccines; 2017 Jan; 16(1):45-54. PubMed ID: 27327875
[TBL] [Abstract][Full Text] [Related]
6. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
Palatnik-de-Sousa CB; Nico D
Front Immunol; 2020; 11():204. PubMed ID: 32210953
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
[TBL] [Abstract][Full Text] [Related]
8. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.
Hoffman SL; Billingsley PF; James E; Richman A; Loyevsky M; Li T; Chakravarty S; Gunasekera A; Chattopadhyay R; Li M; Stafford R; Ahumada A; Epstein JE; Sedegah M; Reyes S; Richie TL; Lyke KE; Edelman R; Laurens MB; Plowe CV; Sim BK
Hum Vaccin; 2010 Jan; 6(1):97-106. PubMed ID: 19946222
[TBL] [Abstract][Full Text] [Related]
9. The Development of Whole Sporozoite Vaccines for
Itsara LS; Zhou Y; Do J; Grieser AM; Vaughan AM; Ghosh AK
Front Immunol; 2018; 9():2748. PubMed ID: 30619241
[TBL] [Abstract][Full Text] [Related]
10. The whole parasite, pre-erythrocytic stage approach to malaria vaccine development: a review.
Epstein JE; Richie TL
Curr Opin Infect Dis; 2013 Oct; 26(5):420-8. PubMed ID: 23982233
[TBL] [Abstract][Full Text] [Related]
11. Live attenuated pre-erythrocytic malaria vaccines.
Keitany GJ; Vignali M; Wang R
Hum Vaccin Immunother; 2014; 10(10):2903-9. PubMed ID: 25483648
[TBL] [Abstract][Full Text] [Related]
12. Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine.
Luke TC; Hoffman SL
J Exp Biol; 2003 Nov; 206(Pt 21):3803-8. PubMed ID: 14506215
[TBL] [Abstract][Full Text] [Related]
13. Designing malaria vaccines to circumvent antigen variability.
Ouattara A; Barry AE; Dutta S; Remarque EJ; Beeson JG; Plowe CV
Vaccine; 2015 Dec; 33(52):7506-12. PubMed ID: 26475447
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered, attenuated whole-cell vaccine approaches for malaria.
Vaughan AM; Wang R; Kappe SH
Hum Vaccin; 2010 Jan; 6(1):107-13. PubMed ID: 19838068
[TBL] [Abstract][Full Text] [Related]
15. Malaria vaccines: are we getting closer?
Epstein JE; Giersing B; Mullen G; Moorthy V; Richie TL
Curr Opin Mol Ther; 2007 Feb; 9(1):12-24. PubMed ID: 17330398
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
[TBL] [Abstract][Full Text] [Related]
17. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Aide P; Sigauque B; Milman J; Mandomando I; Bassat Q; Guinovart C; Espasa M; Corachan S; Lievens M; Navia MM; Dubois MC; Menendez C; Dubovsky F; Cohen J; Thompson R; Ballou WR
Lancet; 2005 Dec; 366(9502):2012-8. PubMed ID: 16338450
[TBL] [Abstract][Full Text] [Related]
18. Genetically attenuated malaria parasites as vaccines.
Vaughan AM; Kappe SHI
Expert Rev Vaccines; 2017 Aug; 16(8):765-767. PubMed ID: 28612631
[No Abstract] [Full Text] [Related]
19. Exploring immunological mechanisms of the whole sporozoite vaccination against P. falciparum malaria.
Mo AX; Pesce J; Hall BF
Vaccine; 2015 Jun; 33(25):2851-7. PubMed ID: 25917675
[TBL] [Abstract][Full Text] [Related]
20. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines.
Richie TL; Billingsley PF; Sim BK; James ER; Chakravarty S; Epstein JE; Lyke KE; Mordmüller B; Alonso P; Duffy PE; Doumbo OK; Sauerwein RW; Tanner M; Abdulla S; Kremsner PG; Seder RA; Hoffman SL
Vaccine; 2015 Dec; 33(52):7452-61. PubMed ID: 26469720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
